Please use this identifier to cite or link to this item:
標題: Increased PD-1 and decreased CD28 expression in chronic hepatitis B patients with advanced hepatocellular carcinoma
作者: Hsu, P.N.
Yang, T.C.
Kao, J.T.
Cheng, K.S.
Lee, Y.J.
Wang, Y.M.
Hsieh, C.T.
Lin, C.W.
Wu, Y.Y.
關鍵字: CD28;hepatocellular carcinoma;PD-1;tumour-infiltrating lymphocytes;cd8(+) t-cells;c virus-infection;chronic viral-infection;infiltrating;lymphocytes;up-regulation;receptor;cd127;proliferation;dysfunction;exhaustion
Project: Liver International
期刊/報告no:: Liver International, Volume 30, Issue 9, Page(s) 1379-1386.
Background/aims: Hepatitis B infection is a well-known cause of hepatocellular carcinoma (HCC). This study aims to investigate the role that the costimulatory molecule CD28 and co-inhibitory molecule programmed death-1 (PD-1) play in compromising the function of tumour-infiltrating lymphocytes (TIL) in hepatitis B virus (HBV)-related HCC. Methods: A total of 45 patients with HBV-related HCC were enrolled during the period February 2008 to March 2010. The immune phenotype and the expression of PD-1, CD28 and CD127 in TIL in biopsy specimens and in peripheral blood lymphocytes (PBL) from the same patients were analysed by flow cytometry. Results: Among the 45 patients, there was a male predominance (80%) and the mean age was 50 +/- 13.68 years (range: 29-71). The majority of TIL were CD45RO(+)CD69(+). PD-1 expression was higher and CD28 and CD127 expression levels were lower in TIL than in PBL. The prevalence of portal vein thrombosis was 40%. Furthermore, tumour thrombosis invasion into the portal vein correlated with the expression level of the PD-1 co-inhibitory molecule. Conclusion: PD-1(+) tumour-infiltrating lymphocytes correlate with portal vein thrombosis and might serve as a potential prognostic marker of and a novel therapeutic target for HBV-related HCC.
ISSN: 1478-3223
DOI: 10.1111/j.1478-3231.2010.02323.x
Appears in Collections:期刊論文

Show full item record

Google ScholarTM




Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.